EP1660636A4 - Vaccins anticancer - Google Patents

Vaccins anticancer

Info

Publication number
EP1660636A4
EP1660636A4 EP04782297A EP04782297A EP1660636A4 EP 1660636 A4 EP1660636 A4 EP 1660636A4 EP 04782297 A EP04782297 A EP 04782297A EP 04782297 A EP04782297 A EP 04782297A EP 1660636 A4 EP1660636 A4 EP 1660636A4
Authority
EP
European Patent Office
Prior art keywords
anticancer vaccines
vaccines
anticancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04782297A
Other languages
German (de)
English (en)
Other versions
EP1660636A2 (fr
Inventor
Jeffrey Molldrem
A John Barrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
US Department of Health and Human Services
Original Assignee
University of Texas System
University of Texas at Austin
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin, US Department of Health and Human Services filed Critical University of Texas System
Publication of EP1660636A2 publication Critical patent/EP1660636A2/fr
Publication of EP1660636A4 publication Critical patent/EP1660636A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4247—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP04782297A 2003-08-26 2004-08-26 Vaccins anticancer Withdrawn EP1660636A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49823803P 2003-08-26 2003-08-26
PCT/US2004/027790 WO2005019435A2 (fr) 2003-08-26 2004-08-26 Vaccins anticancer

Publications (2)

Publication Number Publication Date
EP1660636A2 EP1660636A2 (fr) 2006-05-31
EP1660636A4 true EP1660636A4 (fr) 2009-07-01

Family

ID=34216164

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04782297A Withdrawn EP1660636A4 (fr) 2003-08-26 2004-08-26 Vaccins anticancer
EP04809624A Withdrawn EP1670899A2 (fr) 2003-08-26 2004-08-26 Vaccins contre le cancer, des affections auto-immunes et des infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP04809624A Withdrawn EP1670899A2 (fr) 2003-08-26 2004-08-26 Vaccins contre le cancer, des affections auto-immunes et des infections

Country Status (5)

Country Link
EP (2) EP1660636A4 (fr)
JP (1) JP2007504149A (fr)
AU (1) AU2004267506A1 (fr)
CA (1) CA2536654A1 (fr)
WO (2) WO2005035714A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1874342B1 (fr) * 2005-04-26 2018-06-06 Eisai R&D Management Co., Ltd. Compositions et procédés destinés à l'immunothérapie du cancer
CA2523032A1 (fr) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccins pour la therapie du cancer
CA2700808C (fr) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Utilisation de liposomes dans un vehicule composant une phase hydrophobe continue pour la delivrance de polynucleotides in vivo
WO2009102909A2 (fr) * 2008-02-15 2009-08-20 Board Of Regents, The University Of Texas System Vaccins anti-cancer
ES2524699T3 (es) 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
WO2012079075A1 (fr) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Dérivés de phtalimide deutérés
JP6240077B2 (ja) 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
WO2013130849A1 (fr) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Dérivés de phthalimide dioxopipéridinyle substitués
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
US9643950B2 (en) 2012-10-22 2017-05-09 Concert Pharmaceuticals, Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
WO2014110322A2 (fr) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Dérivés substitués de dioxopipéridinyl phtalimide
EP2762154A3 (fr) * 2013-02-05 2015-01-21 Nitto Denko Corporation Vaccin pour administration transdermique
RU2014102941A (ru) * 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для введения через слизистую оболочку
GB201519303D0 (en) 2015-11-02 2015-12-16 Imp Innovations Ltd Phagemid vector
GB201706451D0 (en) 2017-04-24 2017-06-07 Imp Innovations Ltd Cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449557B2 (en) * 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOLLDREM J ET AL: "TARGETED T-CELL THERAPY FOR HUMAN LEUKEMIA: CYTOTOXIC T LYMPHOCYTESSPECIFIC FOR A PEPTIDE DERIVED FROM PROTEINASE 3 PREFERENTIALLY LYSE HUMAN MYELOID LEUKEMIA CELLS", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 88, no. 7, 1 October 1996 (1996-10-01), pages 2450 - 2457, XP000884740, ISSN: 0006-4971 *
MOLLDREM J J ET AL: "Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 6, no. 9, 1 September 2000 (2000-09-01), pages 1018 - 1023, XP002993663, ISSN: 1078-8956 *
MOLLDREM JEFFREY J ET AL: "Peptide Vaccination with PR1 Elicits Active T Cell Immunity That Induces Cytogenetic Remission in Acute Myelogenous Leukemia.", BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), & 44TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; PHILADELPHIA, PA, USA; DECEMBER 06-10, 2002, pages Abstract No. 8, XP008106166, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
JP2007504149A (ja) 2007-03-01
EP1660636A2 (fr) 2006-05-31
WO2005019435A8 (fr) 2006-04-27
WO2005019435A2 (fr) 2005-03-03
WO2005019435A3 (fr) 2006-06-29
WO2005035714A3 (fr) 2009-04-16
CA2536654A1 (fr) 2005-03-03
WO2005035714A2 (fr) 2005-04-21
AU2004267506A1 (en) 2005-03-03
EP1670899A2 (fr) 2006-06-21

Similar Documents

Publication Publication Date Title
MA28609B1 (fr) Vaccins
EP1678292A4 (fr) Vaccins mva ameliores
MA28885B1 (fr) vaccins
TWI365191B (en) Vaccine
EP1599196A4 (fr) Polytherapies anticancereuses
NO20054608D0 (no) Influensavirusvaksine
DK1959991T3 (da) Terapeutisk vaccine
MA28639B1 (fr) Vaccins
IS8387A (is) Ónæmisvaldandi samsetningar
EP1660636A4 (fr) Vaccins anticancer
GB0329146D0 (en) Vaccine
EP1667701A4 (fr) Vaccin antitumoral
GB0411150D0 (en) Vaccine
IS8325A (is) Bóluefni
GB0305794D0 (en) Vaccine
EP1615614A4 (fr) Vaccin polyvalent optimal contre le cancer
GB0330079D0 (en) Vaccine
GB0305793D0 (en) Vaccine
GB0413510D0 (en) Vaccine
DK1660123T3 (da) Rotavirusvaccine
DK1618130T3 (da) Terapeutisk cancervaccine
EP1646282A4 (fr) Vaccins genetiques anticancereux
GB0412407D0 (en) Vaccine
ATE392435T1 (de) Ostertagia-impfstoff
GB0428381D0 (en) Vaccine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060302

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 1/10 20060101ALI20060707BHEP

Ipc: A61K 39/00 20060101ALI20060707BHEP

Ipc: A61K 38/00 20060101AFI20060707BHEP

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 20060101AFI20070626BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

A4 Supplementary search report drawn up and despatched

Effective date: 20090603

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/00 20060101ALI20090527BHEP

Ipc: A61P 35/02 20060101ALI20090527BHEP

Ipc: A61K 39/00 20060101AFI20090527BHEP

18W Application withdrawn

Effective date: 20090625